📰 Sciences Press News
Page 3 - Sciences Press News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sciences Press. Real-time updates on events, politics, business and more.
March 29, 2022
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in the treatment of sickle cell disease, announced today that the Florida Medicaid...
March 23, 2022
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...
March 4, 2022
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
December 6, 2021
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
November 4, 2021
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
October 26, 2021
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...
August 11, 2021
Similarly, any earnings releases and other press releases and investor communications containing information derived from such financial statements should no longer be relied upon. Emmaus also provided an update on the filing of its delinquent quarterly reports.
August 10, 2021
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial...
July 16, 2021
(OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC). This is the first step in the registration of Endari® by the KDFC, which is responsible for the registration of pharmaceutical products in Kuwait. The KDFC has accepted Emmauss request for fast-track review of Endari®, which is expected to t...